Allergy Diagnostics Market — By Products and Service, By Test Type, By Allergen, By End use – Global Forecast, 2025 to 2034

Allergy Diagnostics Market Size

The global allergy diagnostics market was valued at USD 5.6 billion in 2024. The market is expected to grow from USD 6.1 billion in 2025 to USD 13.4 billion in 2034, at a CAGR of 9.2%. The market growth is driven by the increasing use of molecular diagnostics and AI, expansion of at-home care and point-of-care testing, supportive government reimbursement policies, and growth in personalized therapies, especially immunotherapy and targeted allergy treatments.
 

The need for advanced diagnostic procedures continues to grow due to the rising cases of allergic conditions such as asthma, food allergies, allergic rhinitis, dermatitis, and others. The World Health Organization (WHO) reported that allergies affected nearly 40% of the world's population in 2023 and increased annually by 10-15%. Similarly, the Centers for Disease Control and Prevention (CDC) estimates showed that food allergies in the U.S. reached 32 million in 2022, including 5.6 million children.
 

Social and economic activities that change with climate change and pollution are common risk factors for rising allergies. The European Academy of Allergy and Clinical Immunology (EAACI) in 2023 reported that Allergic Rhinitis affects 24.6% of the European population, which grew by 4% since 2021. This increase has led to higher awareness of the condition among consumers and professionals, driving market growth. Additionally, non-facility based care is moving toward self-administered rapid allergy tests. At-home or point-of-care diagnostic kits are preferred because they are easy to use, give quick results, and reduce the burden on the healthcare system. Telemedicine appointments with allergy
 

 specialists help deliver services to distant regions, improve market access, and make remote healthcare easier, supporting growth in the coming years.
 

Allergy diagnostics includes all procedures that help identify specific allergens that cause allergic reactions in a person. These include skin and blood tests as well as challenge tests to check sensitivity to allergens such as pollen, dust, food, and pet hair, which help create treatment plans for the individual.
 

Allergy Diagnostics Market Trends

• The market is likely to expand with developments in artificial intelligence, at-home testing, and molecular testing for individual allergies. There is more allergy awareness and initiatives toward precision medicine which enhance techniques and methods to manage allergies.
   
• There is noteworthy transition to component-resolved diagnostics (CRD) at the molecular level, which alters how we detect allergens accurately. This will improve personalized allergy treatments while reducing wrong diagnoses. The use of microarray-based tests and next-generation sequencing (NGS) will also help the industry grow.
   
• Data pertaining to allergic reactions to certain foods demonstrates the gaps in diagnostic capabilities. Approximately 32 million people in the U.S. suffer from food allergies as stated by the CDC. Urban living, pollution, and climate change are primary drivers for the increase in cases of asthma, rhinitis, and food allergies and highlights the need for advanced technologies for testing.
   
• According to a study by the EAACI shows that one in three Europeans will have health complications stemming from allergies in 2024 and the global spending on allergy services has increased by 25% from 2021 to 2023, adding to the economic burden of allergies. The study also notes that allergy diagnosis methods are getting more advanced, which shows growing concerns about allergies worldwide.
   
• AI and machine learning algorithms are now used in allergy diagnosis to improve accuracy, speed, predictive analysis, and overall efficiency. The increased automation in skin prick and blood sample testing has improved productivity and accuracy in laboratories. This aids in the timely provision of results. Further, optimization AI diagnostic tools are expected to enhance the productivity of clinicians which is expected to drive growth in the entire market. 
   
• There is increasing investment aimed at providing reliable allergy testing where patients need it, which is also a driver of growth of the market. Development of handheld immunoassay devices and biosensors that would help patients depend less on central laboratories. In addition, remote consultations as well as interpretation of diagnostic tests are being incorporated into telemedicine, thereby extending healthcare access in rural and underserved regions.
   

Allergy Diagnostics Market Analysis

The market by products and services is segmented into services, consumables, and instruments. The services segment continues to dominate, securing a substantial market share valued at USD 2.8 billion in 2024.
 

• Due to the high inventory equipment costs and low in-house proficiency, numerous hospitals, clinics, and even small diagnostic centers are outsourcing their allergy testing to specialized laboratories. This increases the supply of allergy testing services, while simultaneously enhancing the structural peripheral diagnostic service providers.
   
• In addition, the growing implementation of telemedicine has enabled patients to have remote access to allergy consultations as well as diagnostic services. The utilization of telehealth services has sharply increased to 85% in 2022 from 75% in 2021, according to the American Medical Association, marking a significant rise.
   

Based on test type, the allergy diagnostics market is categorized into in vivo and in vitro. The in vivo segment held a dominant market share and accounted for USD 3.5 billion in 2024.
 

• In vivo techniques, like skin prick tests (SPT), intradermal tests, and many other in vivo test types, are known to be the most popular due to their effectiveness and timely results. These tests show immediate allergic responses that allow for multiple allergens to be diagnosed, such as pollen, dust mites, food, and even insect venom.
   
• In addition, the in vivo allergy testing is more affordable than the in vitro (blood-based) test and has proven to be especially useful in cost-sensitive markets. As per the median estimates, the in vivo skin prick testing reimbursement stands at 7-9 USD for the procedures, while in vitro blood tests command a fee of 15-20 USD (CMS, 2023). The NHS UK reported in 2022 that skin tests are about 60 percent cheaper than blood tests in their facilities.
   

Based on allergens, the allergy diagnostics market is categorized into inhaled allergens, food allergens, drug allergens, and other allergens. The inhaled allergens segment held a dominant market share and accounted for USD 2.8 billion in 2024.
 

• The sharp rise in allergic rhinitis, asthma, and chronic respiratory diseases is triggered by inhaled allergens such as pollen, mold spores, dust mites, and pet dander. As a result, there is an increasing need for thorough allergy diagnostics. The AAFA (Asthma and Allergy Foundation of America) reports that over 25 million individuals in the U.S. are asthmatic, with a large number of these cases made worse by environmental allergens.
   
• Also, in allergy tests using whole-allergen extracts, cross-reactivity may occur, causing wrong results. The use of CRD technology allows for better accuracy in identifying specific allergenic proteins from the inhaled matrix, which improves the diagnostics for pollen allergies and allergic asthma.
   

The allergy diagnostics market by end-use is categorized into hospitals-based laboratories, diagnostic laboratories, and other end users. The hospitals-based laboratories segment held a dominant market share and accounted for USD 2.9 billion in 2024.
 

• The growing number of hospital visits for severe allergic reactions, such as anaphylaxis, asthma attacks, and drug allergies, is leading to higher in-house allergy diagnostic requirements. According to CDC Statistics, anaphylaxis-related emergency department visits increased by 29% between 2021 and 2023, with an estimated 218,000 cases in 2023.
   
• Drug allergies have also seen a rise in reported hospital admissions with a reported 15% increase from 2022 to 2024. Rapid-response allergy testing resources for emergency ward and inpatient scenarios are standard services provided by hospital laboratories.
   

 

North America: The U.S. allergy diagnostics market accounted for USD 2.2 billion revenue in 2024 and is anticipated to record robust market growth over the forecast period.
 

• The U.S. market is expected to grow rapidly due to the rising cases of allergic diseases such as asthma, rhinitis, and food allergies. National Security Council data suggests over 50 million Americans are allergy sufferers, out of which 32 million are affected by food allergies. In addition to these factors, increased spending on healthcare and favorable reimbursement policies for allergy testing are also supporting the growth of the market. 
   
• In addition, the detection and customization of treatment is improving through AI-driven diagnostics and telehealth as well as testing at the molecular level. These factors, along with the presence of prominent industry players, extensive research activities, and increasing use of home allergy testing kits, will further drive market growth.
   

Europe: UK allergy diagnostics market is projected to grow remarkably in the coming years.
 

• The UK market is expanding because there is an increased record of allergic conditions and heightened awareness among patients and healthcare providers. The European Academy of Allergy and Clinical Immunology (EAACI) predicts that by 2024, one in three Europeans will have some kind of allergy, thus augmenting the need for advanced diagnostic tools.
   
• Moreover, the NHS has implemented policies towards advanced molecular and AI-based allergy detection across the board. Additionally, the ongoing air pollution along with changing diets and climate change is prompting a rise in allergy cases and increasing the demand for these innovative diagnostic solutions.
   

Japan holds a dominant position in the Asia Pacific allergy diagnostics market.
 

• The Japan market is rapidly growing due to the increasing prevalence of allergic rhinitis, asthma, and food allergies, particularly in children. Increased urbanization, high pollen exposure, and environmental pollution are the main reasons for the increased allergy cases. Allergic healthcare services are well integrated within the country's advanced healthcare infrastructure, and there are strong government initiatives to support allergy research, which are helping the market growth.
   
• Telemedicine and home-based diagnostic tools are improving access to healthcare for the elderly. Advanced Japanese companies are developing molecular diagnostic tools and AI allergy detection systems that improve detection accuracy and efficiency. Japan's fast-growing technology and rising consumer awareness will further drive market growth in the country.
   

Allergy Diagnostics Market Share

A small group of leading players dominates the global market for allergy diagnostics and biotechnology. The competition in this area is quite broad. It has top companies, local small players, start-ups, and everyone else. Major industry players are always active in seeking opportunities within the healthcare industry. The leading companies, including Thermo Fisher Scientific, Danaher, bioMerieux, Siemens Healthineers, and Eurofin Scientific, account for around 25% share in the market. These companies strongly defend their positions in the market with wide portfolios of products and services.
 

These include systems and consumables for allergy diagnostics, servicing, technological innovations, proprietary allergy diagnostic systems and devices, as well as global operations. The sharp increases in product launches from major players are currently driving the market for allergy diagnostics. These launches increase competition and other differentiating factors, prompting companies to meet market demands.
 

There is the possibility for additional innovation within these industries as allergy diagnostics come with newer functionalities and features that improve healthcare standards for users. This helps patients who need easy treatment options along with healthcare practitioners. For instance, in May 2023, Neogen Corporation enhanced their testing offerings with the release of Reveal for Histamine and Reveal Q+ for Histamine. These are used for the rapid detection of histamine using lateral flow tests, a non-chemical method that improves speed and efficiency in detection.
 

This innovation not only advanced Neogen's portfolio in food safety and allergen testing but also boosted the company's competitive position in rapid diagnostic solutions for industries that need fast and accurate automation of histamine evaluation.
 

Allergy Diagnostics Market Companies

Prominent players operating in the allergy diagnostics industry include:

• AgnitioST
• bioMérieux
• Danaher Corporation (Beckman Coulter)
• Eurofins Scientific
• EUROIMMUN
• Excelsior Bio-System
• HollisterStier Allergy
• HYCOR Biomedical
• Lincoln Diagnostics
• Med Phar Enterprise
• Neogen Corporation
• Omega Diagnostics
• REGA BIOTECHNOLOGY
• SGS TAIWAN
• Siemens Healthineers
• Stallergenes Greer
• Thermo Fisher Scientific

• Danaher has automated workflow optimization with high-throughput allergy testing under their Beckman Coulter division. They are first in the industry to incorporate advanced immunoassay technology and AI analytics, enabling fast and accurate results in large-scale allergy diagnostics. Danaher’s strategy seeks to obtain innovative biomarker-based diagnostic testing, expand healthcare provider partnerships, increase diagnostics access, and capture emerging markets in the expanding product portfolio. 
   
• The addition of in-vitro testing services, including molecular allergen component testing and food intolerance screening, has greatly improved comprehensive allergy diagnostics by Eurofins. Their focus is on molecular testing, and with their large global laboratory network, they offer population-specific allergen panels suited to regional allergens. Eurofins is also planning to improve NGS allergy profiling, expand telehealth-compatible diagnostic solutions, and create partnerships with research institutions for better precision diagnostics.
   
• Siemens Healthineers's allergy diagnostics portfolio includes sophisticated immunoassay laboratories equipped with advanced allergiology diagnostic tools. The company's main products are the Atellica and ADVIA platforms, which can be customized, offer high flexibility, and allow accurate and high-throughput tests for many types of allergens. Siemens Healthineers's predictive diagnosis uses AI and cloud data analysis, improving workflow, reducing time-to-results, and enabling precision medicine for allergy management.
   
• Stallergenes Greer's main strengths are AIT (Allergen Immunotherapy Therapy) and allergy diagnostics, making it unique in both allergy treatment and immunotherapy. The company provides customized solutions that combine diagnostic testing and personalized immunotherapy planning. Its strong R&D focus on sublingual and subcutaneous immunotherapy strengthens its market position. Also, Stallergenes Greer works with many health and research institutions to develop new ways to prevent and control allergic diseases long-term.
   
• With the development of ImmunoCAP Technology, which is considered the gold standard in in-vitro allergy testing, Thermo Fisher Scientific entered and grew in the allergy diagnostics market, becoming a leader in the industry. The company focuses on new product development and improving IgE allergen testing for better diagnostic accuracy. They use their strong market position and digital health services to increase global access to allergy diagnostics. The company also invests heavily in using AI to analyze and automate data to improve clinical workflow efficiency while maintaining accurate test results.
   

Allergy Diagnostics Industry News:

• In July 2024, Danaher Corporation launched two CLIA- and CAP-certified laboratories to advance the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). This expansion enhanced the company's diagnostic capabilities, positioning it in precision medicine. This development strengthened Danaher's ability to offer high-precision allergy testing solutions, improve regulatory compliance, and expand partnerships with pharmaceutical companies for personalized allergy treatments.
   
• In October 2022, Eurofins Scientific SE announced the opening of its new 110,000-square-foot laboratory in Lenexa, KS, expanding its capacity for biopharma and transplant diagnostic testing services. The facility, which accommodates 450 employees, including 235 newly created roles, strengthened Eurofins' operational capabilities and workforce. This expansion enhanced the company's ability to meet growing market demand, reinforcing its position in specialized diagnostic testing.
   
• In July 2021, EUROIMMUN announced its strategic collaboration with Immunodiagnostic Systems Holding. This partnership allowed EUROIMMUN to leverage IDS's expertise in random-access automation, chemiluminescence immunoassays, and ELISAs to enhance its portfolio in endocrinology, autoimmune, infection, and allergy diagnostics. The integration strengthened EUROIMMUN's research, development, production, and distribution capabilities, expanding its market presence and reinforcing its position in in vitro diagnostics.
   

Allergy diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2021 to 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product and Service

• Services
• Consumables
• Instruments

Market, By Test Type

• In Vivo
  • Skin prick tests
  • Intradermal skin tests
  • Other in vivo test types 
• In Vitro
  • IgE-based allergy tests
  • IgG-based allergy tests
  • Other in-vitro test types

Market, By Allergens

• Inhaled allergens
• Food allergens
• Drug allergens
• Other allergens

Market, By End use

• Hospitals-based laboratories
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE